PMC:7652766 / 87453-87844 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T127","span":{"begin":318,"end":334},"obj":"Phenotype"}],"attributes":[{"id":"A127","pred":"hp_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/HP_0002721"}],"text":"In the context of discovering new drugs, it is efficient to test the efficacy of existing antiviral drugs regarding the treatment of related viral infections. After the emergence of SARS in 2003, the screening of approved drugs identified an effective SARS-CoV-2 antiviral-drug candidate: the combination of the human immunodeficiency virus (HIV) protease inhibitors lopinavir and ritonavir."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T428","span":{"begin":0,"end":391},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the context of discovering new drugs, it is efficient to test the efficacy of existing antiviral drugs regarding the treatment of related viral infections. After the emergence of SARS in 2003, the screening of approved drugs identified an effective SARS-CoV-2 antiviral-drug candidate: the combination of the human immunodeficiency virus (HIV) protease inhibitors lopinavir and ritonavir."}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"3184","span":{"begin":57,"end":59},"obj":"Gene"},{"id":"3185","span":{"begin":312,"end":340},"obj":"Species"},{"id":"3186","span":{"begin":252,"end":262},"obj":"Species"},{"id":"3187","span":{"begin":342,"end":345},"obj":"Species"},{"id":"3190","span":{"begin":367,"end":376},"obj":"Chemical"},{"id":"3191","span":{"begin":381,"end":390},"obj":"Chemical"},{"id":"3195","span":{"begin":141,"end":157},"obj":"Disease"}],"attributes":[{"id":"A3184","pred":"tao:has_database_id","subj":"3184","obj":"Gene:6999"},{"id":"A3185","pred":"tao:has_database_id","subj":"3185","obj":"Tax:12721"},{"id":"A3186","pred":"tao:has_database_id","subj":"3186","obj":"Tax:2697049"},{"id":"A3187","pred":"tao:has_database_id","subj":"3187","obj":"Tax:12721"},{"id":"A3190","pred":"tao:has_database_id","subj":"3190","obj":"MESH:D061466"},{"id":"A3191","pred":"tao:has_database_id","subj":"3191","obj":"MESH:D019438"},{"id":"A3195","pred":"tao:has_database_id","subj":"3195","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In the context of discovering new drugs, it is efficient to test the efficacy of existing antiviral drugs regarding the treatment of related viral infections. After the emergence of SARS in 2003, the screening of approved drugs identified an effective SARS-CoV-2 antiviral-drug candidate: the combination of the human immunodeficiency virus (HIV) protease inhibitors lopinavir and ritonavir."}